Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma
Phase 3
Terminated
NCT05398263
| Condition | Asthma |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | AstraZeneca |
|---|
| Status | Terminated |
|---|
| Enrollment | 125 participants |
|---|
| Interventions | Tezepelumab |
|---|
| Start date | Aug 9, 2022 |
|---|
| Completion date | Mar 24, 2025 |
|---|
| Results posted | Jun 18, 2026 |
|---|
Summary
A Randomised, Double-Blind, Parallel-Group, Placebo-Controlled 28-week Phase 3 Efficacy and Safety Study of Tezepelumab in Reducing Oral Corticosteroid Use in Adults with Oral Corticosteroid Dependent Asthma
Proportion of Subjects by Categorised Percent Reduction From Baseline in the Daily Maintenance OCS Dose at Week 28 Whilst Maintaining Asthma Control.
Baseline to Week 28 · Participants
| Tezepelumab | 30 Participants |
|---|
| Placebo | 8 Participants |
|---|
| Tezepelumab | 7 Participants |
|---|
| Placebo | 3 Participants |
|---|
| Tezepelumab | 20 Participants |
|---|
| Placebo | 6 Participants |
|---|
| p-value | 0.003 |
|---|
| Cumulative Odds Ratio | 2.93 (95% CI 1.43–6.03) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.